JYPC(SZ:002198)2016-10-20 16:00Financial Performance - Operating revenue for the reporting period was ¥108,586,740.62, representing a year-on-year increase of 10.57%[8]. - Net profit attributable to shareholders was ¥4,474,726.28, a decrease of 53.98% compared to the same period last year[8]. - The net profit after deducting non-recurring gains and losses was ¥4,464,069.45, down 50.08% year-on-year[8]. - Basic earnings per share were ¥0.0088, a decline of 54.17% compared to the previous year[8]. - The weighted average return on net assets was 0.47%, down 0.61 percentage points year-on-year[8]. - Total profit decreased by 23,128,200 yuan, a decline of 45.10%, primarily due to decreased profits from the pharmaceutical distribution business and government subsidies[18]. - Net profit decreased by 21,158,400 yuan, a decline of 50.89%, mainly due to reduced profits from the pharmaceutical distribution business and government subsidies[18]. - The estimated net profit attributable to shareholders for 2016 is projected to be between 51 million and 60 million CNY, representing a decrease of 23.14% to 9.58% compared to the previous year's net profit of approximately 66.35 million CNY[27]. - The decline in net profit is primarily attributed to adjustments in the subsidiary's pharmaceutical distribution business, reduced revenue from trade pharmaceuticals, and a decrease in sales revenue from Jinsan Pharmaceutical[27]. Cash Flow and Expenses - The net cash flow from operating activities decreased by 88.15% to ¥1,884,956.60 for the year-to-date[8]. - Cash received from other operating activities increased by 9,565,400 yuan, a growth of 176.88%, mainly due to increased receivables[19]. - Cash paid for purchasing goods and receiving services decreased by 51,050,100 yuan, a decline of 44.15%, primarily due to reduced payments for pharmaceutical distribution business[19]. - Cash received from investment income decreased by 297,000 yuan, a decline of 100%, mainly due to last year's investment income from financial products[20]. - Cash paid for acquiring fixed assets, intangible assets, and other long-term assets decreased by 10,969,100 yuan, a decline of 68.58%, mainly due to increased investment in the second phase of Jinsan Pharmaceutical last year[21]. - Cash paid for debt repayment decreased by 15,700,000 yuan, a decline of 48.76%, mainly due to reduced bank loan repayments this period[21]. - Financial expenses decreased by 880,000 yuan, a decline of 45.69%, mainly due to reduced interest from loans and bank acceptance bill discounts[18]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,055,935,473.41, an increase of 0.76% compared to the previous year[8]. - Prepaid accounts increased by 420.82% compared to the beginning of the year, mainly due to increased material prepayments[16]. - Other receivables rose by 407.22%, primarily due to increased market development funds paid to various offices[16]. - Accounts payable decreased by 33.85%, mainly due to repayments of raw material payments[17]. Profit Distribution Policy - The company reported a profit distribution policy where cash dividends should not be less than 30% of the average distributable profit over the past three years[25]. - The company plans to actively distribute profits in cash, with a minimum of 10% of distributable profits allocated for the next three years[25]. - In the case of a mature development stage without significant capital expenditure, cash dividends should constitute at least 80% of the profit distribution[25]. - For a mature stage with significant capital expenditures, cash dividends should be at least 40% of the profit distribution[25]. - The company plans to implement cash dividends annually for the next three years, subject to conditions, to align with capital expansion and performance growth[26]. Corporate Governance and Commitments - The company has committed to avoiding any transactions that may harm its interests during the tenure of its directors and senior management[25]. - The company has established a commitment to ensure fair and equitable transactions with related parties[24]. - The company has no plans to engage in any competitive business activities that may conflict with its interests[24]. - The company has a commitment to maintain a minimum of 25% limit on share transfers by directors and senior management during their tenure[25]. - The company has no arrangements for concerted actions with other parties involved in the current issuance[25]. - The company will ensure that any related party transactions are conducted at fair market prices to protect its interests[24]. Investment Income - Investment income from associates and joint ventures increased by 1,380,400 yuan, a growth of 160.81%, primarily due to increased equity investment income from Huqingyuan[18]. Operating Profit - Operating profit decreased by 18,958,100 yuan, a decline of 40.29%, mainly due to reduced profits from the pharmaceutical distribution business[18].